Abstract
Carboplatin is an alkylating antineoplastic drug. Although carboplatin induces apoptosis in rapidly dividing cells like cisplatin, it has fewer side effects. The use of platinum compounds as antineoplastic agents at high doses causes hepatotoxicity, which is important in dose regulation. Levodopa is used as a precursor for dopamine synthesis in the brain in the treatment of Parkinson's disease. Dopamine synthesized in the liver from levodopa cannot cross the blood-brain barrier. There are studies suggesting that dopamine may have a protective effect on hepatocytes. In our study, we aimed to evaluate the cytoprotective effect of levodopa in cell damage induced by carboplatin in the liver cell line. Cell viability was evaluated by MTT test by exposing AML-12 hepatocyte cells to the combination of Carboplatin, L-DOPA and Carboplatin + L-DOPA for 24 hours (0, 3.13, 6.25, 12.5, 25, 50 ,100 µM) has been left. The LD50 value of carboplatin was determined as 62.65 µM. The LD50 values of the combination of L-DOPA and carboplatin + L-DOPA were higher in the tested dose range. The cytotoxic effect of carboplatin on the AML-12 cell line was determined by the increasing LD50 value, which was statistically significantly reduced when combined with levodopa. Further studies are needed to explain the mechanism of action.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Innovative Approaches in Science Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
